MGL 3196

Drug Profile

MGL 3196

Alternative Names: MGL-3196; THR beta agonists - VIA Pharmaceuticals; VIA-3196

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Madrigal Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Nitriles; Pyridazines; Small molecules; Triazines
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Aug 2017 Madrigal Pharmaceuticals completes enrolment in the phase II trial for Non-alcoholic steatohepatitis in USA
  • 14 Jul 2017 Madrigal Pharmaceuticals plans a phase I trial to determine the mass balance of [14C] MGL 3196, in Healthy volunteers in USA (NCT03220165)
  • 02 Jun 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top